We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
All for One, or One for All?
- Abstract
The article presents a case study of a four-year-old suffering from a rare cancer. According to the author, Penelope London was diagnosed when she was just sixteen months old as having an aggressive kind of neuroblastoma. Her cancer recurred later and no treatment was working. After that, her father heard of Neotropix Inc., a company that is developing an experimental drug for cancer. However, the drug is still in the earliest part of safety testing. The U.S. Federal Drug Administration stopped the trial after the first patient in the trial died. The "Wall Street Journal" once described her as dying and in great discomfort. Later on, she was admitted to the New York University Medical Center because her pain medication was ineffective.
- Subjects
UNITED States; NEUROBLASTOMA; LONDON, Penelope; NERVOUS system tumors; NEOTROPIX Inc.; CANCER treatment; UNITED States. Food &; Drug Administration
- Publication
Hastings Center Report, 2007, Vol 37, Issue 4, p13
- ISSN
0093-0334
- Publication type
Case Study
- DOI
10.1353/hcr.2007.0049